

A provider briefing on Clenpiq availability in 2026: supply status, prescribing implications, alternatives, cost considerations, and tools to help.
Clenpiq (Sodium Picosulfate, Magnesium Oxide, and Anhydrous Citric Acid) has become a preferred bowel preparation for many gastroenterology practices and their patients. Its low-volume, ready-to-drink format leads to high completion rates and strong patient satisfaction — 98% of patients in clinical trials reported willingness to repeat the prep.
However, providers across the country are hearing a familiar complaint from patients: "My pharmacy doesn't have Clenpiq." This briefing covers what you need to know about Clenpiq's supply status, prescribing implications, and practical strategies for ensuring your patients are adequately prepared for their procedures.
Clenpiq is manufactured exclusively by Ferring Pharmaceuticals. As of early 2026, it is not listed on the FDA Drug Shortage Database, meaning no formal supply disruption has been reported by the manufacturer.
However, the practical reality at the pharmacy level tells a different story. Clenpiq remains a brand-only product with no generic equivalent. Many retail pharmacies — particularly large chains — do not routinely stock it due to its intermittent demand profile. This creates persistent availability gaps that mimic the effects of a shortage, even when manufacturer supply is stable.
This pattern has been consistent since Clenpiq's initial FDA approval in 2012. As a single-source, procedure-specific medication, it has always required more proactive prescribing and dispensing workflows than daily-use medications.
The availability challenges around Clenpiq have several implications for prescribers:
Prescribing Clenpiq at the time of colonoscopy scheduling — rather than a few days before the procedure — gives pharmacies adequate time to order and stock the medication. A lead time of 7–14 days significantly reduces the risk of patients arriving at their appointment without having completed an adequate prep.
Consider advising patients to check availability before filling their prescription. Independent pharmacies and specialty pharmacies are often more reliable sources for procedure-specific medications like Clenpiq. Tools like Medfinder for Providers can help your practice identify pharmacies with current stock.
Having a backup bowel prep protocol is essential. When Clenpiq is unavailable, the most commonly substituted alternatives include:
Each alternative has different contraindication profiles. For patients with renal impairment, cardiac history, or electrolyte disorders, carefully evaluate the substitute prep's safety profile. For a patient-facing comparison, see: Alternatives to Clenpiq.
The availability of Clenpiq varies significantly by region and pharmacy type:
Understanding the cost landscape helps when discussing options with patients:
For patients where cost is a barrier, generic Suprep ($30–$80) or generic MoviPrep ($20–$60) represent significantly more affordable alternatives. More details: How to Help Patients Save Money on Clenpiq.
Several resources can help your practice navigate Clenpiq availability challenges:
Several trends will likely affect Clenpiq availability in the coming years:
For practices that rely heavily on Clenpiq, maintaining flexible prep protocols with pre-identified alternatives remains the most effective strategy for avoiding procedure cancellations.
Clenpiq is not in an official shortage, but real-world availability continues to challenge practices and patients. Proactive prescribing, early Rx submission, flexible backup protocols, and tools like Medfinder can minimize disruptions to your colonoscopy schedule. Ultimately, the goal is to ensure no patient delays screening because of a bowel prep access issue.
For patient-facing resources on this topic, consider sharing: Clenpiq Shortage Update: What Patients Need to Know.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.